Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
In a show of bipartisanship and further support of precision medicine and health care innovation—including genomics and other diagnostic innovations…
From - Diagnostic Testing & Emerging Technologies
Precision medicine and biomarkers can help the U.S. Food and Drug Administration (FDA) ensure safety of…
From - Diagnostic Testing & Emerging Technologies
Consumers buying direct-to-consumer personal genome tests (DTC-PGT) want to believe…
From - Diagnostic Testing & Emerging Technologies
With Theranos' recent announcement of its transition away from laboratory operations toward technology development…
From - Diagnostic Testing & Emerging Technologies
Summer may be over but the fight against the mosquito-borne virus, Zika, continues in earnest. Locally-mosquito-transmitted cases in…
From - Diagnostic Testing & Emerging Technologies
Increasing diagnostic options for providers and patients was a common theme throughout panel discussions and presentations at…